Ophthalmology Times - Ophthalmology news, articles, and events

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops

Carl D. Regillo, MD, shares insights on the VERONA trial of EYP-1901 at the Retina World Congress 2025 meeting held in Fort Lauderdale, Florida.

By Monique M. Barbour, MD
Matt Hoffman

Q&A: Dilsher S. Dhoot, MD, on the HELIOS trial for diabetic retinopathy

Discover how dropless cataract surgery enhances patient comfort and outcomes, reducing the need for eye drops and improving recovery efficiency.

Belantamab mafodotin–induced corneal changes in patients with multiple myeloma

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs)

By Lynda Charters

RWC 2025: Katherine Talcott, MD, discusses the potential connection of auto-immune conditions to AMD

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential impacts on vision and ocular health.

RWC 2025: Alan J. Franklin, MD, PhD on the use of intraoperative fluorescein angiography

This large database study explored the link between autoimmune problems and AMD.

Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma

In this conversation, Franklin discussed a research study on intraoperative fluorescein angiography in surgical procedures, highlighting significant advancements in surgical visualization and patient outcomes.

By Jordana Joy

ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management

Perfuse Therapeutics reveals promising results for PER-001, a groundbreaking glaucoma treatment, enhancing vision and ocular health in clinical trials.

By Deborah Ristvedt, DO
Sheryl Stevenson

Optigo Bio receives People’s Choice Award for its proprietary drug anchoring

Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians.

By Kassi Filkins

Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics

Optigo Biotherapeutics presents promising preclinical data at ARVO.

By Emily Kaiser Maharjan

Results of phase 2 clinical SAGA study of oral gildeuretinol for GA presented at ARVO 2025

Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME

Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD.

By Jordana Joy

Beacon Therapeutics shares 6-month interim safety and efficacy results from Phase 2 DAWN study for XLRP

Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to improve patient outcomes.

Assessment of AI-enabled screening for ROP in low-resource settings

Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.

By Lynda Charters